# Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

> clinical trial · VERIFIED · 2026-07-16

Status: NOT_YET_RECRUITING · Sponsor: Mayo Clinic · Condition: Glioblastoma, IDH-Wildtype

- Company: Mayo Clinic
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07708961

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.